Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed universal chimeric antigen receptor T (UCAR-T) cells enhances antitumor efficacy in multiple myeloma in the xenograft model. This evidence concerns the gene CD47 and plasma cell myeloma.